FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged >12yrs) with moderate to severe hidradenitis suppurativa https://t.co/G1BtS15sWT

Links:

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with m… https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-app…
Dr. John Cush
RheumNow
Mar-17-2026
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×